The Miao Formula MYYAT Augments the Antitumor Activity of Cisplatin in Small Cell Lung Cancer Models and is Associated with Changes in SHP2–PI3K/mTOR Signaling
Cancer Management and Research · 2026-11 · Volume 18 · 1-21
DOI: 10.2147/cmar.s637368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Management and Research, 2026-11. Verfasst von Xiao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Second Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, People's Republic of China.
- Intensive Care Unit, Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Chinese Medicine, Leshan, People's Republic of China.
- Department of Respiratory Medicine, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, People's Republic of China.
ORCID-Profile: Xiao Li
Zitieren
APA
Li, X., Yu, M., Yang, Y., Zhang, J., Luo, X., Wang, K., Zhu, G., He, L., Li, B., & Ge, Z. (2026). The Miao Formula MYYAT Augments the Antitumor Activity of Cisplatin in Small Cell Lung Cancer Models and is Associated with Changes in SHP2–PI3K/mTOR Signaling. Cancer Management and Research, Volume 18, 1-21. https://doi.org/10.2147/cmar.s637368
Vancouver
Li X, Yu M, Yang Y, Zhang J, Luo X, Wang K, et al. The Miao Formula MYYAT Augments the Antitumor Activity of Cisplatin in Small Cell Lung Cancer Models and is Associated with Changes in SHP2–PI3K/mTOR Signaling. Cancer Management and Research. 2026;Volume 18:1-21. doi:10.2147/cmar.s637368
BibTeX
@article{Li2026,
author = {Li, Xiao and Yu, Mei and Yang, Yi and Zhang, Jun and Luo, Xian and Wang, Kelin and Zhu, Guoqing and He, Liu and Li, Bo and Ge, Zhengxing},
title = {The Miao Formula MYYAT Augments the Antitumor Activity of Cisplatin in Small Cell Lung Cancer Models and is Associated with Changes in SHP2–PI3K/mTOR Signaling},
journal = {Cancer Management and Research},
year = {2026},
volume = {Volume 18},
pages = {1--21},
doi = {10.2147/cmar.s637368}
}
EUVIMED